Search

827 Result(s)
Sort by

More Green Overview

More Green Overview

Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
Green Chemistry

Green Chemistry

Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
Be green Japan

Be green Japan

Boehringer Ingelheim's Yamagata site is gradually switching to a more sustainable energy supply.
More Cherished Moments

More Cherished Moments

Innovation in healthcare is about more than just a new approach or technology. We innovate for better health of people and animals.
garbage game

garbage game

Learn more about marine pollution and find out how long it takes for garbage to dissolve in the oceans.
More Potential Overview

More Potential Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Making more health through animal health

Making more health through animal health

Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
More Than Scleroderma

More Than Scleroderma

A hub of knowledge, advice and support for those whose lives have been touched by scleroderma.
More Health Overview

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
More health in vulnerable communities

More health in vulnerable communities

In an era of globalization and social connectivity, one-dimensional solutions often do not work anymore. Complex challenges need complex solutions.
More Potential

More Potential

Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million